Visionary Holdings (GV) Company Report

Visionary Holdings Inc. (GV) has officially launched its medical-grade stem cell anti-aging product line, initially targeting the Chinese mainland and broader Asian markets.
This launch follows GV's strategic partnership and global technology licensing agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. ("Yike"), integrating Yike's proprietary regenerative technologies into GV's solutions.
The product portfolio includes a Comprehensive Regenerative Package, Precision Repair Package, and Premium Personalized Program, designed for high-net-worth individuals and clients with specific conditions.
GV plans to expand its sales and distribution network to include Canada, the United States, and Mexico, in addition to its initial Asian market focus.
The Company's CEO anticipates this product line will serve as a new driver of profitability in upcoming fiscal years.

Nov 10, 2025, 2:30 PM

Visionary Holdings Inc. Announces Leadership and Governance Restructuring

Board Change

CEO Change

CFO Change

Visionary Holdings Inc. convened the First Meeting of its Fourth Board of Directors on November 3, 2025, successfully completing key deployments to optimize its governance structure and form a new core team.
A new Board of Directors was elected, with Mr. William T. Chai as Chairman and Mr. Kealey Donald M as Vice Chairman.
Four specialized committees were formally established: Audit, Nomination, Compensation, and Investment.
A new senior management team was appointed, including Mr. Xiyong Hou as Chief Executive Officer (CEO), Mr. Jun Huang as Co-Chief Executive Officer (Co-CEO), Mr. Robert Jay LEES as Chief Operating Officer (COO), and Ms. Xiaolan Liu as Chief Financial Officer (CFO).

Nov 4, 2025, 2:30 PM

Visionary Holdings Inc. 2025 AGM Concludes, Elects New Board, Reappoints Auditor

Board Change

Auditor Change

Proxy Vote Outcomes

Visionary Holdings Inc. (GV) held its 2025 Annual General Meeting (AGM) on October 31, 2025, where all proposals were approved by an overwhelming majority.
Nine candidates were elected to the 4th Session of the Board of Directors, and Assentsure PAC was reappointed as the company's auditor for the 2025-2026 fiscal year.
For the 2024-2025 fiscal year, core businesses accounted for 78% of revenue, new big health projects achieved 100% year-on-year net profit growth, total assets were stable at USD 68,792 thousand, and the asset-liability ratio was 80%.
The company's strategic focus for the next fiscal year includes improving core businesses, accelerating emerging businesses, and strengthening compliant governance.

Oct 31, 2025, 1:30 PM

Visionary Holdings Launches Stem Cell Joint Venture in Toronto

New Projects/Investments

Product Launch

Visionary Holdings (GV) has established Visionary Yike Stemcell Technologies Inc., a Canada-based joint venture with Jiangsu Yike Regenerative Medical Technology Co., Ltd.
The joint venture aims to advance stem cell research, clinical application, and commercialization worldwide, initially focusing on stem cell therapy, immune cell engineering, and AI-supported anti-aging diagnostics and intervention models.
GV will hold an 85% equity stake in the joint venture, with Yike holding 15%.
The intended headquarters for the joint venture is GV's property complex at 95–105 Moatfield Drive, Toronto, Ontario, a former IBM headquarters with over 40,000 square meters of space.
This collaboration seeks to advance the clinical application and commercialization of Yike's breakthrough stem cell technology for Type 1 and Type 2 diabetes.

Oct 22, 2025, 1:30 PM

Visionary Holdings Completes Controlling Stake in Sikang Health Industry Joint Venture

New Projects/Investments

M&A

Visionary Holdings Inc. (GV) has completed an equity adjustment to obtain a 51% controlling stake in Sikang (Guangzhou) Health Industry Investment Co., Ltd., a joint venture established with Guangzhou Sikang Investment Holding Co., Ltd..
This transaction, announced on October 17, 2025, marks a key step in Visionary's strategy of "global high-quality industry investment" to promote standardized services and global expansion in the Traditional Chinese Medicine (TCM) health preservation sector.
The joint venture, initially formed in December 2024, aims to integrate Visionary's capital and global resources with Guangzhou Sikang's operational experience to drive the systematic global layout of TCM health preservation.
The Joint Venture Platform has already initiated expansion into the Southeast Asian market (Malaysia) as of September 22, 2025, and strengthened domestic channel cooperation on October 7, 2025.
Visionary's management expects this controlling stake to empower the Joint Venture Platform with compliant capital support, global industrial channels, and resource integration, ultimately building a dual growth curve of "industrial investment + business operation" and creating long-term shareholder value.

Oct 17, 2025, 1:30 PM

GV Secures Global License for Diabetes Stem Cell Technology

New Projects/Investments

Product Launch

Revenue Acceleration/Inflection

Visionary Holdings (GV), through its wholly owned subsidiary Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd. (Yike).
This agreement grants GV worldwide rights to apply Yike's breakthrough stem cell technology, which has demonstrated potential for long-term remission and even complete cure for both Type 1 and Type 2 diabetes.
The global diabetes treatment market is projected to exceed USD 150 billion in 2024.
The collaboration features a revenue-sharing arrangement, where GV will benefit from market sales and brand operations, while Yike will generate revenue from technology licensing and clinical R&D.
GV's CEO, Xiyong Hou, expects this collaboration to significantly contribute to the company's revenue growth in upcoming fiscal years by leveraging its international commercialization network.

Oct 13, 2025, 1:40 PM

Visionary Holdings (Asia) Limited Signs Strategic Cooperation Agreement with Qianxin Bocheng (Jiangsu)

New Projects/Investments

M&A

Visionary Holdings (Asia) Limited, a wholly owned subsidiary of Visionary Holdings Inc. (Nasdaq: GV), has entered into a strategic cooperation agreement with Qianxin Bocheng (Jiangsu) Technology Development Co., Ltd., an accelerator and industrial park operator.
The partnership aims to advance the aesthetic treatment industry by combining Qianxin Bocheng's policy support, funding, and industrial park facilities with Visionary Holdings (Asia)'s operational oversight, capital resources, and international experience.
The cooperation framework covers industrial park cooperation, project incubation, enterprise cultivation and M&A channels, and brand and promotional activities.
Visionary Holdings (Asia) will have priority to acquire or strategically invest in high-quality projects to integrate them into the GV platform, enhancing industry competitiveness and creating long-term shareholder value.
The agreement is effective for three years, with renewal subject to mutual agreement.